These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions. Vázquez-Borrego MC; Fuentes-Fayos AC; Gahete MD; Castaño JP; Kineman RD; Luque RM Cell Physiol Biochem; 2018; 49(4):1444-1459. PubMed ID: 30205369 [TBL] [Abstract][Full Text] [Related]
6. Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis. Huang N; Feng Y; Liu Y; Zhang Y; Liu L; Zhang B; Zhang T; Su Z; Xue L; Wu ZB Int Immunopharmacol; 2024 Jun; 134():112159. PubMed ID: 38692018 [TBL] [Abstract][Full Text] [Related]
7. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution? Herrera-Martínez AD; Pedraza-Arevalo S; L-López F; Gahete MD; Gálvez-Moreno MA; Castaño JP; Luque RM J Clin Endocrinol Metab; 2019 Jan; 104(1):57-73. PubMed ID: 30265346 [TBL] [Abstract][Full Text] [Related]
9. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)]. Nagamine T; Fukuda I No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068 [TBL] [Abstract][Full Text] [Related]
10. Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin. Luque RM; Kineman RD J Endocrinol; 2018 Jun; 237(3):217-227. PubMed ID: 29615476 [TBL] [Abstract][Full Text] [Related]
11. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer. Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590 [TBL] [Abstract][Full Text] [Related]
12. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors. Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171 [TBL] [Abstract][Full Text] [Related]
13. Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway. Li J; Song H; Chen T; Zhang S; Zhang C; Ma C; Zhang L; Wang T; Qian Y; Deng X Neuroendocrinology; 2024; 114(6):589-601. PubMed ID: 38565081 [TBL] [Abstract][Full Text] [Related]
14. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells. Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701 [TBL] [Abstract][Full Text] [Related]
15. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation. Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708 [TBL] [Abstract][Full Text] [Related]
16. Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. An J; Pei X; Zang Z; Zhou Z; Hu J; Zheng X; Zhang Y; He J; Duan L; Shen R; Zhang W; Zhu F; Li S; Yang H Oncotarget; 2017 Jun; 8(23):37538-37549. PubMed ID: 28380462 [TBL] [Abstract][Full Text] [Related]